Stephen Eeden to 5-alpha Reductase Inhibitors
This is a "connection" page, showing publications Stephen Eeden has written about 5-alpha Reductase Inhibitors.
Connection Strength
0.599
-
The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality. Urology. 2018 Sep; 119:70-78.
Score: 0.317
-
5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. Mayo Clin Proc. 2016 Dec; 91(12):1717-1726.
Score: 0.283